Nascent Biotech Inc. has engaged HRA Capital to help raise capital to fund the continual development of Pritumumab, a drug to treat brain cancer, through its phase 1 and phase 2 clinical trials.
Discover more about S&P Global’s offerings
HRA Capital to help raise funds for Nascent Biotech's brain cancer drug
Commercial Banking: June 22nd Edition
Understanding Loss Given Default A Review of Three Approaches
Commercial Banking Newsletter June Edition - 2022
Insight Weekly: US recession outlook; mortgage activity slowdown; climate disclosure push
Nascent Biotech Inc. has engaged HRA Capital to help raise capital to fund the continual development of Pritumumab, a drug to treat brain cancer, through its phase 1 and phase 2 clinical trials.